CCO Management Series
Management of ER+ Postmenopausal Early Breast Cancer
Expert faculty present compelling clinical data on the use of predictive factors for guiding treatment decisions, as well as therapeutic strategies and safety profiles associated with the use of tamoxifen and aromatase inhibitors.
Virtual Presentations
The Role of Predictive Factors in Guiding Treatment Decisions for ER-Positive Postmenopausal Breast Cancer
- William J. Gradishar, MD, FACP
|
|
|
 William J. Gradishar, MD, FACP, reviews predictive factors and prognostic assays used to stratify postmenopausal patients with early breast cancer and guide treatment decisions. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe how to optimize selection of endocrine treatments for breast cancer patients
- Discuss patient characteristics, tumor characteristics, genetic profiles, estrogen receptor levels, and other markers and models to assess risk, and the need for chemotherapy in addition to hormonal therapy
- Cite data comparing different prognostic signatures in making treatment choices for predicting benefit in breast cancer patients
|
The Role of Predictive Factors in Guiding Treatment Decisions for ER-Positive Postmenopausal Breast Cancer
 |
|
Downloadable slideset focused on predictive factors and prognostic assays used to stratify postmenopausal patients with early breast cancer to help guide treatment decisions.
Format: Microsoft PowerPoint (.ppt) | File size: 2,286 KB
|
Current Hormonal Therapy Strategies for ER-Positive Postmenopausal Breast Cancer
|
|
|
Ruth M. O’Regan, MD, reviews the clinical management of postmenopausal patients with early breast cancer receiving hormonal therapy. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe current hormonal treatment strategies for estrogen receptor–positive postmenopausal breast cancer patients
- Discuss the mechanism of action of aromatase inhibitors
- Cite clinical trial efficacy data supporting the use of tamoxifen or aromatase inhibitors in estrogen receptor–positive postmenopausal early breast cancer patients
|
Current Hormonal Therapy Strategies for ER-Positive Postmenopausal Breast Cancer
 |
|
Downloadable slideset reviews the clinical management of postmenopausal patients with early breast cancer receiving hormonal therapy
Format: Microsoft PowerPoint (.ppt) | File size: 717 KB
|
Evaluating Long-Term Safety of Aromatase Inhibitors
- Paul E. Goss, MD, PhD, FRCPC, FRCP
|
|
|
Paul E. Goss, MD, PhD, FRCPC, FRCP, reviews the long-term safety profiles of tamoxifen and aromatase inhibitors for the treatment of postmenopausal patients with early breast cancer. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the safety results of clinical trials using tamoxifen and aromatase inhibitors in the treatment of postmenopausal patients with estrogen receptor–positive breast cancer
- Discuss the role of estrogen in the treatment and prevention of breast cancer
- Cite the risks and benefits associated with endocrine therapies for breast cancer treatment
- Recount the effects that aromatase inhibitors have on end organs
|
Evaluating Long-Term Safety of Aromatase Inhibitors
 |
|
Downloadable slideset focused on the long-term safety issues associated with the use of tamoxifen and aromatase inhbitors
Format: Microsoft PowerPoint (.ppt) | File size: 5,299 KB
|
Clinical Case: Treatment Options for an ER-Positive Postmenopausal Woman With Early Breast Cancer (coming soon)
Program Director:
Paul Goss, MD, PhD, FRCPC, FRCP (UK)
- Harold J. Burstein, MD, PhD
|
|
|
|
CME Modules
The Role of Predictive Factors in Guiding Treatment Decisions for ER-Positive Postmenopausal Breast Cancer (coming soon)
Program Director:
Paul Goss, MD, PhD, FRCPC, FRCP (UK)
- William J. Gradishar, MD, FACP
|
|
|
|
Current Hormonal Therapy Strategies for Estrogen Receptor–Positive Postmenopausal Breast Cancer
Program Director:
Paul E. Goss, MD, PhD, FRCPC, FRCP
|
|
 Topics covered include:
- Introduction
- ATAC Trial: Anastrozole vs Tamoxifen
- BIG 1-98: Letrozole vs Tamoxifen
- IES: Tamoxifen vs Tamoxifen Followed By Exemestane
- Anastrozole Sequencing Studies
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe current hormonal treatment strategies for ER-positive postmenopausal breast cancer patients
- Discuss the mechanism of action of aromatase inhibitors
- Cite clinical trial efficacy data supporting the use of tamoxifen or aromatase inhibitors in ER-positive postmenopausal early-stage breast cancer patients
|
Evaluating Long-Term Safety of Aromatase Inhibitors
Program Director:
Paul E. Goss, MD, PhD, FRCPC, FRCP
- Paul E. Goss, MD, PhD, FRCPC, FRCP
|
|
|
Paul E. Goss, MD, PhD, FRCPC, FRCP, reviews the safety profiles associated with the long-term use of aromatase inhibitors. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the safety results of clinical trials using tamoxifen and aromatase inhibitors in the treatment of postmenopausal patients with estrogen receptor–positive breast cancer
- Discuss the role of estrogen in the treatment and prevention of breast cancer
- Cite the risks and benefits associated with endocrine therapies for breast cancer treatment
- Recount the effects that aromatase inhibitors have on end organs
|
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|